美股异动｜诺和诺德盘前涨超1%

Core Viewpoint - Novo Nordisk's Amycretin Phase II clinical trial results show significant reductions in both weight and HbA1c (glycated hemoglobin) among participants, leading to a pre-market stock increase of over 1% [1] Company Summary - Novo Nordisk's stock experienced a pre-market increase of over 1% following positive clinical trial results [1] - The Phase II clinical trial for Amycretin demonstrated significant improvements in patient outcomes, specifically in weight and HbA1c levels [1]